—
The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.Get Sample Report @ https://www.wiseguyreports.com/sample-request/383562-amyloidosis-pipeline-review-h1-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Amyloidosis
- The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects
- The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Amyloidosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Amyloidosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Amyloidosis Overview 10
Therapeutics Development 11
Pipeline Products for Amyloidosis - Overview 11
Pipeline Products for Amyloidosis - Comparative Analysis 12
Amyloidosis - Therapeutics under Development by Companies 13
Amyloidosis - Therapeutics under Investigation by Universities/Institutes 15
Amyloidosis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Amyloidosis - Products under Development by Companies 19
Amyloidosis - Products under Investigation by Universities/Institutes 21
Amyloidosis - Companies Involved in Therapeutics Development 22
Alnylam Pharmaceuticals, Inc. 22
Arcturus Therapeutics, Inc 23
Bellus Health Inc. 24
Bsim2 25
Celgene Corporation 26
GlaxoSmithKline Plc 27
Neurimmune Holding AG 28
NeuroPhage Pharmaceuticals, Inc. 29
Onyx Pharmaceuticals, Inc. 30
Pfizer Inc. 31
Prothena Corporation Plc 32
SOM Innovation Biotech SL 33
Takeda Pharmaceutical Company Limited 34
Amyloidosis - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ALN-ANG - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ALN-TTRsc02 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
carfilzomib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CLR-01 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eprodisate disodium - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
GSK-2315698 + GSK-2398852 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Access Report @ https://www.wiseguyreports.com/reports/383562-amyloidosis-pipeline-review-h1-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 144945
Google
RSS